Almirall: psoriasis drug gets European Commission approval
(CercleFinance.com) - Spain's Almirall said on Tuesday that the European Commission has approved the use of its monoclonal antibody Ilumetri (tildrakizumab) for the treatment of adult patients with moderate-to-severe chronic plaque psoriasis.
The drug is expected to be rolled out in Europe in the next few weeks, with Germany the first country to launch the product.
Almirall shares were up 2.7% on this news in Madrid.
Tildrakizumab blocks interleukin-23 (IL-23), an upstream inflammatory mediator cytokine, with a limited impact on the rest of the immune system.
It is administered by subcutaneous injection, every 3 months during maintenance.
According to clinical trials, an average of 63% of patients achieved 75% skin clearance after 12 weeks of treatment.
Copyright (c) 2018 CercleFinance.com. All rights reserved.
The drug is expected to be rolled out in Europe in the next few weeks, with Germany the first country to launch the product.
Almirall shares were up 2.7% on this news in Madrid.
Tildrakizumab blocks interleukin-23 (IL-23), an upstream inflammatory mediator cytokine, with a limited impact on the rest of the immune system.
It is administered by subcutaneous injection, every 3 months during maintenance.
According to clinical trials, an average of 63% of patients achieved 75% skin clearance after 12 weeks of treatment.
Copyright (c) 2018 CercleFinance.com. All rights reserved.